TREATMENT WITH A COMBINATION OF LOW-DENSITY-LIPOPROTEIN APHAERESIS AND PRAVASTATIN OF A PATIENT WITH DRUG-RESISTANT NEPHROTIC SYNDROME DUE TO FOCAL SEGMENTAL GLOMERULOSCLEROSIS

被引：29

作者：

HATTORI, M

ITO, K

KAWAGUCHI, H

TANAKA, T

KUBOTA, R

KHONO, M

机构：

[1] Department of Paediatric Nephrology, Kidney Centre, Tokyo Women's Medical College, Tokyo

来源：

PEDIATRIC NEPHROLOGY | 1993年 / 7卷 / 02期

关键词：

LOW-DENSITY LIPOPROTEIN APHAERESIS; PRAVASTATIN; NEPHROTIC SYNDROME; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; HYPERLIPEMIA;

D O I：

10.1007/BF00864397

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Results of recent animal studies have lent support to the hypothesis that hyperlipidaemia may contribute to renal injury. This report documents the case of a 15-year-old boy with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis (FGS) who showed an improvement in renal function and proteinuria as a result of treatment with low-density lipoprotein aphaeresis (LDL-A) combined with pravastatin. Although further work is required to determine the efficacy of lipid-lowering therapy in progressive glomerular disease in humans, the combination of LDL-A and pravastatin is likely be included in the choice of treatment modalities available for patients with drug-resistant nephrotic syndrome due to FGS.

引用

页码：196 / 198

页数：3

共 14 条

[1]

Moorhead J.F., Lipids and progressive kidney disease, Kidney Int, 39, pp. S35-S40, (1991)

[2]

Keane W.F., Mulcahy W.S., Kasiske B.L., Kim Y., O'Donnell M.P., Hyperlipidemia and progressive renal disease, Kidney Int, 39, pp. S41-S48, (1991)

[3]

Tojo K., Sakai S., Miyahara T., Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS), Jpn J Nephrol, 30, pp. 1153-1160, (1988)

[4]

Yokoyama S., Hayashi R., Kikkawa T., Tani N., Takada S., Hatanaka K., Yamamoto A., Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis: characterization and experimental use in hypercholesterolemic rabbits, Arteriosclerosis, 4, pp. 276-282, (1984)

[5]

Mabuchi H., Michishita I., Takeda M., Fujita H., Koizumi J., Takeda R., Takada S., Oonishi M., A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis), Atherosclerosis, 68, pp. 19-25, (1987)

[6]

Diamond J.R., Karnovsky M.J., Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation, Kidney Int, 32, pp. 671-677, (1987)

[7]

Harris K.P.G., Purkerson M.L., Yates J., Klahr S., Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome, Am J Kidney Dis, 15, pp. 16-23, (1990)

[8]

Rabelink A.J., Hene R.J., Erkelens D.W., Joles J.A., Koomans H.A., Partial remission of nephrotic syndrome in patient on long-term simvastatin, Lancet, 335, pp. 1045-1046, (1990)

[9]

Strauss J., Zilleruelo G., Freundlich M., Abitol C., Less commonly recognized features of childhood nephrotic syndrome, Pediatr Clin North Am, 34, pp. 591-590, (1987)

[10]

Block L.H., Pletscher A., Low-density lipoprotein: an old substance with a new function?, TIPS, 9, pp. 214-216, (1988)

← 1 2 →